Advances in the Quest for Safe and Effective Drugs That Target the Cannabinoid Receptor Type 1 (CB1)

Doaa M. Hanafy; Boris P. Budiono; Abishek B. Santhakumar; David J. Leaver

doi:10.1021/acsmedchemlett.5c00402

Advances in the Quest for Safe and Effective Drugs That Target the Cannabinoid Receptor Type 1 (CB1)

Doaa M. Hanafy
, Boris P. Budiono
, Abishek B. Santhakumar
, David J. Leaver

Research output: Contribution to journal › Review article › peer-review

Abstract

Pain management costs the world billions of dollars each year, and there are limited nonopioid options to treat people suffering from chronic pain. Opioids are excellent analgesics but are liable to abuse and fatal overdoses. This Microperspective summarizes challenges and opportunities pertaining to creating nonopioid drugs that could be used to treat chronic pain, substance abuse, fatty liver, or obesity by targeting the cannabinoid receptor type 1 (CB1).

Original language	English
Pages (from-to)	2120-2129
Number of pages	10
Journal	ACS Medicinal Chemistry Letters
Volume	16
Issue number	11
DOIs	https://doi.org/10.1021/acsmedchemlett.5c00402
Publication status	Published - 13 Nov 2025
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

analgesics
CB1
chronic pain
clinical trials
synthetic cannabinoid receptor agonists

Access to Document

10.1021/acsmedchemlett.5c00402Licence: In Copyright

Cite this

@article{03772659f4a447afbc89de25e129569a,

title = "Advances in the Quest for Safe and Effective Drugs That Target the Cannabinoid Receptor Type 1 (CB1)",

abstract = "Pain management costs the world billions of dollars each year, and there are limited nonopioid options to treat people suffering from chronic pain. Opioids are excellent analgesics but are liable to abuse and fatal overdoses. This Microperspective summarizes challenges and opportunities pertaining to creating nonopioid drugs that could be used to treat chronic pain, substance abuse, fatty liver, or obesity by targeting the cannabinoid receptor type 1 (CB1).",

keywords = "analgesics, CB1, chronic pain, clinical trials, synthetic cannabinoid receptor agonists",

author = "Hanafy, \{Doaa M.\} and Budiono, \{Boris P.\} and Santhakumar, \{Abishek B.\} and Leaver, \{David J.\}",

year = "2025",

month = nov,

day = "13",

doi = "10.1021/acsmedchemlett.5c00402",

language = "English",

volume = "16",

pages = "2120--2129",

journal = "ACS Medicinal Chemistry Letters",

issn = "1948-5875",

publisher = "American Chemical Society",

number = "11",

}

TY - JOUR

T1 - Advances in the Quest for Safe and Effective Drugs That Target the Cannabinoid Receptor Type 1 (CB1)

AU - Hanafy, Doaa M.

AU - Budiono, Boris P.

AU - Santhakumar, Abishek B.

AU - Leaver, David J.

PY - 2025/11/13

Y1 - 2025/11/13

N2 - Pain management costs the world billions of dollars each year, and there are limited nonopioid options to treat people suffering from chronic pain. Opioids are excellent analgesics but are liable to abuse and fatal overdoses. This Microperspective summarizes challenges and opportunities pertaining to creating nonopioid drugs that could be used to treat chronic pain, substance abuse, fatty liver, or obesity by targeting the cannabinoid receptor type 1 (CB1).

AB - Pain management costs the world billions of dollars each year, and there are limited nonopioid options to treat people suffering from chronic pain. Opioids are excellent analgesics but are liable to abuse and fatal overdoses. This Microperspective summarizes challenges and opportunities pertaining to creating nonopioid drugs that could be used to treat chronic pain, substance abuse, fatty liver, or obesity by targeting the cannabinoid receptor type 1 (CB1).

KW - analgesics

KW - CB1

KW - chronic pain

KW - clinical trials

KW - synthetic cannabinoid receptor agonists

UR - https://www.scopus.com/pages/publications/105021967742

U2 - 10.1021/acsmedchemlett.5c00402

DO - 10.1021/acsmedchemlett.5c00402

M3 - Review article

AN - SCOPUS:105021967742

SN - 1948-5875

VL - 16

SP - 2120

EP - 2129

JO - ACS Medicinal Chemistry Letters

JF - ACS Medicinal Chemistry Letters

IS - 11

ER -

Advances in the Quest for Safe and Effective Drugs That Target the Cannabinoid Receptor Type 1 (CB1)

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this